Perrigo Company PLC

Noticias y eventos de Perrigo Company PLC (PRGO)

$16.630

+0.151 (+0.91%)Al cierre

Noticias de PRGO

Eventos de PRGO

10/9 16:30

Rumor of Perrigo Takeover Highlighted in Blog

A rumor regarding Perrigo was highlighted in Ben Harrington's takeover-focused Betaville blog, contacts tell The Fly.

8/5 07:00

Company Lowers FY26 Revenue Outlook by 1.5%-5.5%

Backs FY26 revenue view down 1.5%-5.5%. The company said, "The Company reaffirms its 2026 outlook. Second-half results are expected to benefit from the moderation of planned under absorption stemming from lower prior-year sales volumes, more favorable category comparisons, lower interest expense, continued cost benefits from the Operational Enhancement Program and progress across the Company's key growth initiatives, including innovation, distribution gains and demand generation. As indicated previously, planned under absorption stemming from lower prior-year sales volumes is expected to result in an unfavorable All In EPS impact of approximately $0.60 in 2026. Approximately $0.26 of that impact was recognized in the first quarter and $0.18 was recognized in the second quarter. The Company continues to closely monitor the consumer and macroeconomic environment."

8/5 07:00

Company Reports Q2 Revenue of $1.02B, Exceeding Expectations

Reports Q2 revenue $1.02B, consensus $1.01B. "We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt," said Albert Manzone, Interim President and Chief Executive Officer. "While results were impacted by ongoing category softness and macroeconomic headwinds, we again drove market share gains as our broad portfolio of quality self-care products across all price points continues to resonate with consumers seeking value and affordability. We also took another important step in simplifying our portfolio by completing the previously announced sale of our Dermacosmetics business, and are continuing the strategic reviews of our Infant Formula and Oral Care businesses. We are becoming a more focused consumer self-care company, and are making progress in strengthening the underlying fundamentals of our business."

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar